Anidulafungin Dosing
For invasive candidiasis and candidemia, administer anidulafungin with a 200 mg loading dose on day 1, followed by 100 mg daily maintenance dose; for esophageal candidiasis, use a 100 mg loading dose on day 1, followed by 50 mg daily maintenance dose. No dose adjustments are required for renal or hepatic impairment 1.
Standard Dosing Regimens
Invasive Candidiasis/Candidemia (Adults)
- Loading dose: 200 mg IV on Day 1
- Maintenance dose: 100 mg IV once daily
- Duration: At least 14 days after the last positive blood culture and resolution of symptoms 2, 1
The 2016 IDSA guidelines strongly recommend echinocandins, including anidulafungin with this exact dosing regimen, as first-line therapy for candidemia and invasive candidiasis 2.
Esophageal Candidiasis (Adults)
- Loading dose: 100 mg IV on Day 1
- Maintenance dose: 50 mg IV once daily
- Duration: Minimum 14 days and at least 7 days following resolution of symptoms 2, 1
Pediatric Dosing (≥1 month of age)
For candidemia and invasive Candida infections:
- Loading dose: 3 mg/kg (not to exceed 200 mg) on Day 1
- Maintenance dose: 1.5 mg/kg (not to exceed 100 mg) once daily 1
Important: Anidulafungin is not approved for esophageal candidiasis in pediatric patients 1.
Administration Details
Infusion Rate
Never exceed 1.1 mg/minute (equivalent to 1.4 mL/minute or 84 mL/hour when properly reconstituted and diluted) 1. This rate limitation reduces the risk of histamine-mediated infusion reactions including rash, urticaria, flushing, pruritus, bronchospasm, and hypotension 1.
Dose Adjustments
No Adjustments Required For:
- Renal impairment (any degree, including dialysis) - anidulafungin is not renally excreted or dialyzable 1, 3
- Hepatic impairment (any degree) - anidulafungin undergoes non-hepatic degradation 3
- Elderly patients - no age-based adjustment needed
Special Populations Requiring Consideration:
Morbidly obese patients (>140 kg): Recent pharmacokinetic data suggests standard dosing may result in suboptimal exposure in patients weighing more than 140 kg 4. Consider a 25% dose increase (loading dose 250 mg, maintenance 125 mg) in this population, though this is not yet reflected in official labeling 5, 4.
Critically ill patients: A 2025 study found that only 45% of critically ill patients achieved adequate pharmacokinetic targets on early treatment days with standard dosing 5. Both body weight and serum albumin significantly impact target attainment. However, until further evidence emerges, maintain standard dosing while monitoring clinical response closely.
Clinical Context and Pitfalls
When to Use Anidulafungin
The IDSA guidelines position anidulafungin as:
- First-line for candidemia and invasive candidiasis in critically ill patients 2
- Alternative for empiric therapy in ICU patients with suspected invasive candidiasis 2
- Option for chronic disseminated candidiasis (several weeks of therapy) 2
- High-dose option (200 mg daily) for native valve endocarditis 2
Critical Warnings
- Esophageal candidiasis limitation: Anidulafungin is associated with high relapse rates in esophageal candidiasis 1, 6. Fluconazole remains preferred when susceptible organisms are present 2, 6.
- Pediatric contraindications: Not approved for patients <1 month of age due to polysorbate 80 content, which can cause thrombocytopenia, renal dysfunction, and metabolic acidosis in low-birth-weight infants 1
- Hereditary Fructose Intolerance: Absolute contraindication - anidulafungin contains fructose and can cause life-threatening metabolic crisis 1
Common Dosing Errors to Avoid
Real-world data shows that while anidulafungin loading and maintenance doses are generally prescribed correctly (55.6% received appropriate 200 mg loading dose), some institutions use non-standard regimens 7, 8. Always use the FDA-approved loading dose strategy - it is essential for rapid achievement of therapeutic concentrations.